Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer.
Sanomachi T, Okuma HS, Kitadai R, Kawachi A, Yazaki S, Tokura M, Arakaki M, Saito A, Kita S, Yamamoto K, Maejima A, Kojima Y, Nishikawa T, Sudo K, Shimoi T, Noguchi E, Fujiwara Y, Sugino H, Shiino S, Suto A, Yoshida M, Yonemori K.
Sanomachi T, et al. Among authors: kojima y.
Front Oncol. 2023 Mar 27;13:1157789. doi: 10.3389/fonc.2023.1157789. eCollection 2023.
Front Oncol. 2023.
PMID: 37051545
Free PMC article.